Amylyx Pharmaceuticals Inc AMLX

$27.79 -0.29 (-1.03%)

Valuation

Market cap
3,128,758,000
Revenue TTM
$0
Net income TTM
$-144,740,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
912,300
Avg volume
2,585,780
Day's range
$27.64 – $28.81
Shares out
111,423,000
Stochastic %K
4%
Beta
-0.10
Analysts
Strong Sell
Price target
$40.82

Price

Company profile

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsu...

Show more

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
617 682 0917
Website
https://amylyx.com
Address
55 Cambridge Parkway, Suite 6W, Cambridge, United States

Latest news

Stocktwits

SilentBull69 Oct 2, 4:50 PM
$AMLX For the love of God, would y’all please stop shorting this company…. They now have life-changing products …and all you “shorts” just wanna beat it down . And that goes directly to all you institutional investors here ….as you keep lending your shares out to short …shame on every one of you ..😡 I hope ALL “shorts” get burned here very soon 
0 replies
ajmore Oct 1, 7:07 PM
$AMLX new U.S. ICD-10-CM code for post-bariatric hypoglycemia (PBH)—the condition relevant to Amylyx's avexitide—then yes: it became effective today, October 1, 2026. The new code is E89.830 — Post bariatric hypoglycemia. It is part of the FY2027 ICD-10-CM code set, which applies to services from October 1, 2026 through September 30, 2027. CMS +2 That's significant for PBH because previously clinicians generally had to use broader hypoglycemia codes such as E16.1 (Other hypoglycemia) together with bariatric-surgery status. The CDC proposal specifically noted that this did not accurately identify PBH patients. Target 70 (with ALS and Wolfram target 100)
1 replies
SilentBull69 Oct 1, 2:44 PM
$AMLX This current situation is all wrong…. Were these institutions that own 95% of AMLX …are constantly lending out their shares to short. From the perspective of a long shareholder, it’s completely backwards: …”If you’re invested alongside me because you believe the shares have value, why are you collecting a lending fee to provide ammunition to somebody betting on the opposite outcome?” And even when AMLX gets constructive analyst commentary this morning, …including a $45 Stifel target …..we STILL see a constant sell off. AMLX is doing great …..and none of this downtrend is related to the company operations…… it’s directly related to the very institutions that claim they’re backing the company.
0 replies
11thestate Oct 1, 1:30 PM
Amylyx Pharmaceuticals ($AMLX) Is Moving Toward an FDA Filing After Positive Phase 3 Results Amylyx reported positive Phase 3 results for avexitide, an investigational treatment for post-bariatric hypoglycemia. The trial showed a 55% reduction in hypoglycemic events compared with placebo, while also meeting all secondary endpoints. https://www.amylyx.com/news The company now plans to submit an NDA to the FDA by the end of 2026, with a potential commercial launch in 2027 if approved. Avexitide has also received FDA Breakthrough Therapy and Orphan Drug designations. https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-announces-positive-topline-results-0 Amylyx has also raised approximately $500M to support development and potential commercialization, and recently entered manufacturing agreements to support future avexitide supply if approved. The news comes after Relyvrio was withdrawn in 2024 following a failed Phase 3 trial, which also led to a $6.5M investor settlement. https://11th.com/cases/amylyx-pharmaceutical-investor-settlement
0 replies
Quantumup Oct 1, 12:55 PM
Stifel reiterated $AMLX Buy; PT $45 $CRNX VRTX $RYTM MBX VOGX ASND RICFY ZLDPF ZLDPY RZLT Here's what Stifel said in its note: https://x.com/Quantumup1/status/2105642692264731118?s=20
0 replies
SilentBull69 Sep 30, 6:01 PM
$AMLX ….this is downward, Pressure ..practically 100% of it is from “short selling” ….and you know who’s behind it… the institutions themselves …. as they lend out their shares to short 13.51 million shares short, just in the last two weeks alone 😡
0 replies
LoveRetailFroth Sep 30, 5:15 PM
$AMLX Conservative revenue of 3 Billion. Conservative multiple of 3. 10 Billion market cap here soon.
0 replies
LoveRetailFroth Sep 30, 4:52 PM
$AMLX Yeah CHRONIC rare disease! 8% growth a yr. $60 🚀
0 replies